Clinical data | |
---|---|
Trade names | Tracleer, Stayveer, Safebo |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605001 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 50% |
Protein binding | >98% |
Metabolism | Liver |
Elimination half-life | 5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.171.206 |
Chemical and physical data | |
Formula | C27H29N5O6S |
Molar mass | 551.62 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Bosentan, sold under the brand name Tracleer among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH).[4][5]
Bosentan is available as film-coated tablets (62.5 mg or 125 mg) or as dispersable tablets for oral suspension (32 mg).[4]
UKlabel2017
was invoked but never defined (see the help page).